Array BioPharma Inc. the National Comprehensive Cancer Network has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include Braftovi in combination with Mektovi and an anti-EGFR antibody as a Category IIa treatment for patients with BRAFV600E-mutant metastatic colorectal cancer, after failure of one or two prior lines of therapy for metastatic disease.
“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.
